drugset / Trial / NCT05270863
Safety and Efficacy Study BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic or Pseudophakic Presbyopia
RandomizedCrossoverDouble-blindTreatment
Summary
Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia
Timeline
- Start
- 2022-03-30
- Primary completion
- 2023-03-17
- Completion
- 2023-04-10
Outcome
Met primary endpoint
registry NUMBER BRIMOCHOL™ PF: 49.4 (41.9 to 57.0) Percentage of participants NCT05270863 ↗
registry analysis (superiority test); BRIMOCHOL™ PF vs Carbachol PF vs Brimonidine Tartrate; p <.001; Regression, Logistic NCT05270863 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BRIMOCHOL | Unknown | — | Topical |
| Comparator | Brimonidine | Unknown | — | Other |
| Comparator | CARBAMOYLCHOLINE | Small molecule | — | Topical |